CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 138 enrolled
Drug / intervention
LY3857210 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05630196
NCT05630196Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Chronic Low Back Pain

Eli Lilly and Company·interventional·Posted Nov 29, 2022·Updated Aug 13, 2024

In Brief

A Phase 2 clinical trial evaluating LY3857210 and Placebo for Chronic Low-back Pain. Completed, enrolled 138 participants across 30 sites in 2 countries.

Detailed Summary

The main purpose of this study is to assess whether LY3857210 is safe and efficacious in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Low-back Pain
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedNov 29, 2022
Enrollment StartDec 8, 2022
Primary CompletionJun 9, 2023
Study CompletionJun 15, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.6 years ago

Interventions

LY3857210drug

Administered orally

Placebodrug

Administered orally